BridgeBio Pharma, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BridgeBio announced FDA acceptance of its NDA for oral infigratinib for children with achondroplasia, granted Priority Review with PDUFA target action date of February 4, 2027. PROPEL 3 met primary endpoint (annualized height velocity +2.10 cm/year, p<0.0001) and key secondary endpoints, with first-ever statistically significant improvements in body proportionality and arm span in an achondroplasia Phase 3 trial. If approved, oral infigratinib would be the first and only oral therapy for this indication; BridgeBio plans U.S. launch upon approval and European MAA submission in Q4 2026.
Why this rating
Major regulatory milestone for lead candidate targeting orphan pediatric indication; potential first-mover advantage as sole oral option. Material to pipeline but modest relative to $7.3B market cap. Approval not assured; approval risk and commercial execution risks remain.
Tradability signal
NO TRADE
No trade: positive news with only -0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.19% over 4 hrs, n=76). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $65.46 | +10 min · unknown $65.40 ▼ 0.09% | +30 min · unknown $64.68 ▼ 1.19% | +1 hr · unknown $64.08 ▼ 2.11% | +4 hrs · unknown $63.42 ▼ 3.12% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.